Product
ARI0003
1 clinical trial
2 indications
Indication
Refractory Non-Hodgkin LymphomaIndication
Non-Hodgkin LymphomaClinical trial
First in Human, Pilot, Open-label, Prospective, Multicentre, Non-randomised Clinical Trial to Evaluate the Safety and Efficacy of ARI0003 (CART CD19/ CD269 Cells) in Patients With Relapsed/Refractory B-cell Aggressive LymphomaStatus: Not yet recruiting, Estimated PCD: 2025-04-15